In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year Heart Failure death. Results of IMPEDANCE-HF extended trial

Session Moderated Poster Session - Acute heart failure

Speaker Michael Kleiner Shochat

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Moderated Posters

Authors : M Kleiner Shochat (Hadera,IL), D Kapustin (Toronto,CA), M Fudim (Durham,US), M Kazatsker (Hadera,IL), Y Levy (Hadera,IL), A Asif (Hadera,IL), I Kleiner (Beer Sheva,IL), JM Weinstein (Beer Sheva,IL), G Panjrath (Washington,US), A Roguin (Hadera,IL), S Meisel (Hadera,IL)

M Kleiner Shochat1 , D Kapustin2 , M Fudim3 , M Kazatsker1 , Y Levy1 , A Asif1 , I Kleiner4 , JM Weinstein4 , G Panjrath5 , A Roguin1 , S Meisel1 , 1Hillel Yaffe Medical Center, Heart Institute - Hadera - Israel , 2University of Toronto, Internal disease - Toronto - Canada , 3Duke University Medical Center, Cardiology - Durham - United States of America , 4Saroka Medical Center, Cardiology - Beer Sheva - Israel , 5George Washington University School of Medicine and Health Sciences, Cardiology - Washington - United States of America ,


The aim of secondary analyses of  the IMPEDANCE-HF extended trial was to find out if residual congestion on discharge for HF could predict 30-day and one-year Heart Failure death.

The analysis of IMPEDANCE-HF extended trial was based on the data collected during the index hospitalization for HF. The IMPEDANCE-HF extended trial was a randomized controlled single-blinded trial of HF with reduced LVEF patients. Inclusion criteria were LVEF = 45%, NYHA class II-IV and patients were hospitalized for HF within 12 months ( NCT01315223). Half of the patients (N=145) were assigned to the active Lung Impedance (LI)-guided treatment arm where clinicians were based therapy on LI level. The other half was assigned to the control arm where LI values were recorded but not conveyed to the clinical treatment team. In the case of hospitalization, LI was recorded in all patients at discharge. The decisions regarding discharge and choice of treatment were at the discretion of the hospital staff .

A non-invasive impedance device was used in this study to assess the lung fluid content. Unlike the existing impedance devices, the present device has the ability to differentiate a true signal from the lungs from the noise signal of surrounding chest wall. Such approach enables to measure a small change in lung fluid content. A method to determine individual "dry" baseline LI (BLI) for each HF patient has been reported. BLI for each patient was used to calculate a new parameter, the ?LIR= [(current LI/BLI)-1] ×100%, which determinate the degree of pulmonary congestion in time of measurement.

Method. Degree of pulmonary congestion at discharge for HF hospitalization was divided into 5 brackets. (1) ?LIR= 0 to – 18% - minimal interstitial edema (IE), (2) ?LIR= - 18.1 to -28% - mild IE, (3) ?LIR= -28.1 to – 38 – moderate IE, (4) ?LIR= -38.1 to -48% - severe IE to mild alveolar edema (AE) and (5) ?LIR < -48.1% - moderate AE.


LI-guided patients were followed for 61.9.4±39.6 months and control patients for 46.7±33.3 months (p<0.01) accounting for 269 and 470 HF hospitalizations, respectively (p<0.01). Twenty-five (38%) and 57 (66%) HF-associated deaths were recorded during follow-up (p<0.01) representing a mortality rate of 0.03 and 0.1 per patient×year follow up in the LI-guided and control group, respectively (p<0.01). Probability of HF death within 30-day and one year is presented on figure. Conclusion The degree of pre-discharge pulmonary congestion as assessed by LI is a very robust and reliable predictor for 30-day and one-year HF death.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are